Stock AMLX AMYLYX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Real-time Estimate Cboe BZX
Other stock markets
 12:55:42 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.875 USD +6.53% Intraday chart for Amylyx Pharmaceuticals, Inc. -5.05% -87.23%
Apr. 11 Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating MT
Apr. 10 Transcript : Amylyx Pharmaceuticals, Inc. - Special Call

Evolution of the average Target Price on Amylyx Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c84cdcc0.B5s1EaQgTXnRXV3X6TxjvbrF7-iygUImZ7iJoSF-OlM.VvRAS9F4egGbPCqk3k4EyfKTuoPt-RdzA4zc-2wXXyZX0gNb8VR4M6RoCA~d3997e3bf8a481633569252abd4129f8

Analyst Recommendations on Amylyx Pharmaceuticals, Inc.

Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating MT
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating MT
Mizuho Downgrades Amylyx Pharmaceuticals to Neutral From Buy After Negative Results From Phase 3 PHEONIX Study, Adjusts PT to $4 From $32 MT
H.C. Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $42, Maintains Buy Rating MT
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $8 From $36, Maintains Buy Rating MT
Goldman Sachs Downgrades Amylyx Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $40 MT
Leerink Partners Downgrades Amylyx Pharmaceuticals to Market Perform From Outperform MT
Baird Downgrades Amylyx Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $4 From $37 MT
Mizuho Securities Ups Price Target on Amylyx Pharmaceuticals to $32 From $27 on New Revenue Contributions by PSP, Wolfram Therapies, Keeps Buy Rating MT
Baird Starts Amylyx Pharmaceuticals With Outperform Rating, $37 Price Target MT
Mizuho Slashes Price Target on Amylyx Pharmaceuticals to $27 From $46, Keeps Buy Rating MT
Deutsche Bank Initiates Coverage on Amylyx Pharmaceuticals With Buy Rating, $36 Price Target MT
Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $40 From $46, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $42 From $50, Keeps Buy Rating MT
Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $46 From $48, Keeps Buy Rating MT
Goldman Sachs Upgrades Amylyx Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $49 From $45 MT
Mizuho Securities Cuts Amylyx Pharmaceuticals' Price Target to $50 From $52, Buy Rating Kept MT
Citigroup Trims Amylyx Pharmaceuticals' Price Target to $53 From $54, Buy Rating Kept MT
Goldman Sachs Cuts Amylyx Pharmaceuticals' Price Target to $45 From $47, Neutral Rating Kept MT
Mizuho Initiates Amylyx Pharmaceuticals at Buy With $52 Price Target MT
Goldman Sachs Adjusts Amylyx Pharmaceuticals Price Target to $47 From $41, Maintains Neutral Rating MT
Citigroup Adjusts Amylyx Pharmaceuticals Price Target to $54 From $51, Maintains Buy Rating MT
BofA Securities Initiates Coverage on Amylyx Pharmaceuticals With Buy Rating, $50 Price Target MT
HC Wainwright Adjusts Price Target on Amylyx Pharmaceuticals to $50 From $35, Reiterates Buy Rating MT
Citigroup Raises Amylyx Pharmaceuticals Price Target to $50 From $48, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
1.76 USD
Average target price
4.25 USD
Spread / Average Target
+141.48%
High Price Target
8 USD
Spread / Highest target
+354.55%
Low Price Target
3 USD
Spread / Lowest Target
+70.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Amylyx Pharmaceuticals, Inc.

Baird
Deutsche Bank Securities
Mizuho Securities
HC Wainwright
Leerink Partners
Goldman Sachs
Citigroup
BofA Securities
SVB Securities LLC
SVB Leerink
Evercore ISI

Ratings for Amylyx Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AMLX Stock
  4. Consensus Amylyx Pharmaceuticals, Inc.